Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 133 and Ondansetron DDI Study in Overweight/Obesity
NCT07310563Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (4 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration and 1 more. Started Dec 2024; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07310563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07310563.